Financial reports
NT 10-K
Notice of late annual filing
31 Mar 23
10-Q
2022 Q3
Quarterly report
21 Nov 22
NT 10-Q
Notice of late quarterly filing
14 Nov 22
10-Q
2022 Q2
Quarterly report
22 Aug 22
NT 10-Q
Notice of late quarterly filing
15 Aug 22
10-Q
2022 Q1
Quarterly report
23 May 22
NT 10-Q
Notice of late quarterly filing
16 May 22
10-K
2021 FY
Annual report
11 Apr 22
NT 10-K
Notice of late annual filing
30 Mar 22
10-Q
2021 Q3
Quarterly report
15 Nov 21
Current reports
8-K
Entry into a Material Definitive Agreement
28 Feb 23
8-K
Entry into a Material Definitive Agreement
12 Oct 22
8-K
Changes in Registrant's Certifying Accountant
17 Aug 22
8-K
NutraLife BioSciences, Inc. Finalizes Product Registration with U.S. FDA & Completes First Order of Oral Shield Mouth Spray
18 Dec 20
8-K
NutraLife BioSciences, Inc. Provides Company Update
12 Nov 20
8-K
Entry into a Material Definitive Agreement
5 Nov 20
8-K
Changes in Registrant's Certifying Accountant
3 Nov 20
8-K
Regulation FD Disclosure
27 Oct 20
8-K
Other Events
30 Mar 20
8-K
Entry into a Material Definitive Agreement
28 Feb 20
Registration and prospectus
D
$200K in options, sold $25K, 1 investor
30 Dec 20
D
$100K in options, sold $100K, 3 investors
8 Dec 20
D
$500.2K in equity, sold $55.02K, 2 investors
3 Sep 20
S-8
Registration of securities for employees
18 Jul 18
10-12G/A
Registration of securities (amended)
22 Feb 18
10-12G/A
Registration of securities (amended)
4 Dec 17
10-12G
Registration of securities
1 Nov 17
D/A
Indefinite amount in other securities, sold $205K, 5 investors
1 Jun 17
D
Indefinite amount in other securities, sold $205K, 4 investors
1 Jun 17
D/A
$1.64M in other securities, sold $1.64M, 51 investors
1 Jun 17
Other
UPLOAD
Letter from SEC
13 Mar 18
UPLOAD
Letter from SEC
5 Jan 18
CORRESP
Correspondence with SEC
15 Dec 17
UPLOAD
Letter from SEC
13 Dec 17
UPLOAD
Letter from SEC
28 Nov 17
CORRESP
Correspondence with SEC
13 Jan 14
EFFECT
Notice of effectiveness
13 Jan 14
CORRESP
Correspondence with SEC
10 Jan 14
UPLOAD
Letter from SEC
24 Dec 13
UPLOAD
Letter from SEC
14 Nov 13